Overview

Study of Cabozantinib (XL184) Versus Prednisone in Men With Metastatic Castration-resistant Prostate Cancer Previously Treated With Docetaxel and Abiraterone or MDV3100

Status:
Completed

Trial end date:
2015-03-01

Target enrollment:

Participant gender:

Summary

This study will evaluate the effect of cabozantinib compared to prednisone on overall survival in men with previously treated metastatic castration-resistant prostate cancer with bone-dominant disease who have experienced disease progression on docetaxel-containing chemotherapy and abiraterone or MDV3100.

Phase:

Phase 3

Details

Lead Sponsor:

Exelixis

Treatments:

Docetaxel
Prednisone